Ensysce Biosciences Inc. (ENSC)
NASDAQ: ENSC
· Real-Time Price · USD
2.54
0.09 (3.67%)
At close: Oct 03, 2025, 3:58 PM
2.58
1.57%
After-hours: Oct 03, 2025, 07:08 PM EDT
3.67% (1D)
| Bid | 2.4 |
| Market Cap | 6.02M |
| Revenue (ttm) | 7.41M |
| Net Income (ttm) | -6.58M |
| EPS (ttm) | -3.6 |
| PE Ratio (ttm) | -0.71 |
| Forward PE | -49 |
| Analyst | n/a |
| Dividends | n/a |
| Ask | 2.65 |
| Volume | 79,404 |
| Avg. Volume (20D) | 345,279 |
| Open | 2.39 |
| Previous Close | 2.45 |
| Day's Range | 2.39 - 2.55 |
| 52-Week Range | 1.62 - 14.67 |
| Beta | 1.11 |
| Ex-Dividend Date | n/a |
About ENSC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ENSC
Website n/a
Ensysce Biosciences Inc. is scheduled to release its earnings on
Nov 11, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+0.48%
ENSC stock has given up its prior gain. Ensysce Bi...
Unlock content with
Pro Subscription
2 months ago
+0.48%
Ensysce Biosciences shares are trading higher after the company announced it received FDA feedback for PF614-MPAR.
1 month ago · accessnewswire.com
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium~ Experts Spotlight TAAP™ and MPAR® as Next-Generation Solutions for Severe Pain ~ SAN DIEGO, CA / ACCESS Newswire / September 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Comp...
1 month ago · accessnewswire.com
Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~ ~ Ensysce Biopharma Leader to Deliver O...
1 month ago · accessnewswire.com
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program UpdatesInitiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval Receives $5.3 Million Installment from NIDA To Support Overdose Prot...
